Rachel A. Chiaverelli, Executive Director, Oncology Early Translational Biomarkers at GSK, shared on LinkedIn:
“After nearly four incredible years at Daiichi Sankyo, I’m excited to share that I have started a new opportunity as Executive Director, Oncology Early Translational Biomarkers at GSK!
I’m incredibly grateful for my time at Daiichi Sankyo and for the people, experiences, and opportunities that have shaped me.
I’ve had the great privilege of contributing to meaningful science and learning so much along the way.
Thank you to everyone at Daiichi Sankyo that has been a part of my journey!
This new chapter in my career at GSK is particularly meaningful as I am returning to the place that was pivotal in driving my passion for translational medicine early in my career.
I am thrilled to bring my experience and passion for oncology translational medicine from early discovery towards patients in need of novel treatment options!
Here’s to making an impact in oncology!”
You may also be interested in: GSK Bets Up to $750M on Chimagen Trispecific T Cell Engager
